{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:02:50Z","timestamp":1791547370824,"version":"4.3.4"},"reference-count":91,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WI233684"],"award-info":[{"award-number":["WI233684"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["Health-F3-2011-278348"],"award-info":[{"award-number":["Health-F3-2011-278348"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.cmi.2019.03.014","type":"journal-article","created":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T11:52:17Z","timestamp":1553341937000},"page":"951-957","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":229,"title":["Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment"],"prefix":"10.1016","volume":"25","author":[{"given":"E.-T.","family":"Piperaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.S.","family":"Tzouvelekis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Miriagou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.L.","family":"Daikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2019.03.014_bib1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/CMR.00058-16","article-title":"Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges","volume":"30","author":"Wong","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2019.03.014_bib2","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.cmi.2019.03.014_bib3","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/nrd3957-c1","article-title":"The value of single-pathogen antibacterial agents","volume":"12","author":"Spellberg","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.cmi.2019.03.014_bib4","unstructured":"World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. Available\u00a0from: http:\/\/www.who.int\/medicines\/publications\/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf (Accessed 11-11-2018)."},{"key":"10.1016\/j.cmi.2019.03.014_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/668770","volume":"34","author":"Sievert","year":"2013","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.cmi.2019.03.014_bib6","unstructured":"European Centre for Disease Prevention and Control. European antimicrobial resistance surveillance network (EARS-Net) (Available from: https:\/\/ecdc.europa.eu\/en\/about-us\/partnerships-and-networks\/disease-and-laboratory-networks\/ears-net)."},{"key":"10.1016\/j.cmi.2019.03.014_bib7","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.1128\/AAC.01361-08","article-title":"Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria","volume":"8","author":"Plachouras","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib8","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"7","author":"Garonzik","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciw839","article-title":"Dosing guidance for intravenous colistin in critically-ill patients","volume":"64","author":"Nation","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib10","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1128\/AAC.00554-15","article-title":"Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients","volume":"59","author":"Karaiskos","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib11","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1586\/14787210.5.5.811","article-title":"Polymyxin B: similarities to and differences from colistin (polymyxin E)","volume":"5","author":"Kwa","year":"2007","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.cmi.2019.03.014_bib12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cid\/ciu213","article-title":"Colistin and polymyxin B: peas in a pod, or chalk and cheese?","volume":"59","author":"Nation","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib13","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S1473-3099(18)30611-X","article-title":"Colistin for the treatment of multidrug-resistant infections","volume":"18","author":"LaPlante","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib14","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1086\/599225","article-title":"Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center","volume":"48","author":"Hartzell","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib15","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/cid\/cir611","article-title":"Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system","volume":"53","author":"Pogue","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2019.03.014_bib17","first-page":"3291","article-title":"New pharmacokinetic\/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection","volume":"12","author":"Cheah","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib18","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkx409","article-title":"Pharmacokinetics\/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models","volume":"73","author":"Landersdorfer","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib19","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1128\/AAC.04110-14","article-title":"Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii","volume":"59","author":"Bowers","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib20","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.10-0463","article-title":"Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration","volume":"138","author":"Imberti","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.cmi.2019.03.014_bib21","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01367-17","article-title":"Pharmacokinetic\/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients","volume":"61","author":"Forrest","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib22","series-title":"Recommendations for MIC determination of colistin (polymyxin E). 22 March 2016","year":"2016"},{"key":"10.1016\/j.cmi.2019.03.014_bib23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2165\/11317100-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of tigecycline","volume":"48","author":"Barbour","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cmi.2019.03.014_bib24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ijantimicag.2005.02.013","article-title":"Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline","volume":"25","author":"Conte","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.014_bib25","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jac\/dkp056","article-title":"Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model","volume":"63","author":"Koomanachai","year":"2009","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib26","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1128\/AAC.01615-10","article-title":"Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline","volume":"56","author":"Bhavnani","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib27","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/23744235.2018.1423703","article-title":"Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae","volume":"50","author":"Ni","year":"2018","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.cmi.2019.03.014_bib28","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2019.03.014_bib29","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.01232-12","article-title":"Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia","volume":"57","author":"Ramirez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib30","article-title":"Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.cmi.2019.03.014_bib31","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00277-010-0911-7","article-title":"Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline","volume":"89","author":"Pieringer","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cmi.2019.03.014_bib32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijantimicag.2014.07.014","article-title":"High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections","volume":"45","author":"Routsi","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.014_bib33","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1574-6968.1995.tb07357.x","article-title":"Interaction of sulbactam, clavulanic acid and tazobactam with penicillin-binding proteins of imipenem-resistant and -susceptible Acinetobacter baumannii","volume":"125","author":"Urban","year":"1995","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.cmi.2019.03.014_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ijantimicag.2014.02.012","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in\u00a0vitro and murine thigh and lung infection models","volume":"43","author":"Yokoyama","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.014_bib35","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.34.6.958","article-title":"Penetration of ampicillin and sulbactam in the lower airways during respiratory infections","volume":"34","author":"Valcke","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib36","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1128\/AAC.00342-13","article-title":"Pharmacodynamics modeling to optimize dosage regimens of sulbactam","volume":"57","author":"Jaruratanasirikul","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib37","article-title":"OXA-23, a prevalent mechanism contributing to sulbactam resistance in diverse Acinetobacter baumannii clinical strains","volume":"63","author":"Yang","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib38","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-016-0636-6","article-title":"Intravenous minocycline: a review in Acinetobacter infections","volume":"76","author":"Greig","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.cmi.2019.03.014_bib39","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40121-017-0153-2","article-title":"Minocycline for the treatment of multidrug and extensively drug-resistant A.\u00a0baumannii: a review","volume":"6","author":"Lashinsky","year":"2017","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2019.03.014_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01671-18","article-title":"Pharmacodynamics of minocycline against Acinetobacter baumannii in a rat pneumonia model","volume":"63","author":"Tarazi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib41","doi-asserted-by":"crossref","first-page":"S374","DOI":"10.1093\/cid\/ciu613","article-title":"A\u00a0review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections","volume":"59","author":"Ritchie","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0885066610377975","article-title":"Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"25","author":"Chan","year":"2010","journal-title":"J\u00a0Intensive Care Med"},{"key":"10.1016\/j.cmi.2019.03.014_bib43","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ijantimicag.2015.04.002","article-title":"Trimethoprim\/sulfamethoxazole for Acinetobacter spp.: a review of current microbiological and clinical evidence","volume":"46","author":"Falagas","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.014_bib44","article-title":"Trimethoprim\u2013sulfamethoxazole vs. colistin or ampicillin\u2013sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: a retrospective matched cohort study","author":"Raz-Pasteur","year":"2018","journal-title":"J\u00a0Glob Antimicrob Resist"},{"key":"10.1016\/j.cmi.2019.03.014_bib45","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1469-0691.2005.01198.x","article-title":"Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events","volume":"11","author":"Petrosillo","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.03.014_bib46","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jac\/dkm509","article-title":"Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections","volume":"61","author":"Bassetti","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib47","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib48","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1128\/AAC.02435-13","article-title":"Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Sirijatuphat","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib49","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ijantimicag.2013.09.010","article-title":"Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria","volume":"43","author":"Pontikis","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.014_bib50","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1128\/AAC.00871-13","article-title":"Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria","volume":"58","author":"Petrosillo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib51","article-title":"New treatment options against carbapenem-resistant Acinetobacter baumannii infections","volume":"63","author":"Isler","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib52","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S1473-3099(18)30513-9","article-title":"Analysis of the clinical antibacterial and antituberculosis pipeline","volume":"19","author":"Theuretzbacher","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib53","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1007\/s10096-017-3063-z","article-title":"Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens","volume":"36","author":"Dobias","year":"2017","journal-title":"Eur J ClinMicrobiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib54","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01022-17","article-title":"Efficacy of humanized exposures of cefiderocol (S-649266) against a diverse population of Gram-negative bacteria in a murine thigh infection model","volume":"61","author":"Monogue","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib55","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem\u2013cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib56","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In-vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib57","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","article-title":"In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii","volume":"51","author":"Seifert","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.014_bib58","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.cmi.2019.03.014_bib59","article-title":"IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs. meropenem in the treatment of complicated intra-abdominal infections","author":"Solomkin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib60","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.cmi.2019.03.014_bib61","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1473-3099(18)30099-9","article-title":"Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial","volume":"18","author":"Paul","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib62","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/ijccm.IJCCM_302_17","article-title":"Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study","volume":"22","author":"Makris","year":"2018","journal-title":"Indian J Crit Care Med"},{"key":"10.1016\/j.cmi.2019.03.014_bib63","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2019.03.014_bib64","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1093\/jac\/dkn128","article-title":"Ampicillin\/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp","volume":"61","author":"Oliveira","year":"2008","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib65","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1097\/MJT.0b013e3182a32df3","article-title":"Treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam","volume":"23","author":"Zalts","year":"2016","journal-title":"Am J Ther"},{"key":"10.1016\/j.cmi.2019.03.014_bib66","first-page":"432","article-title":"Efficacy and safety of high-dose ampicillin\/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"56","author":"Betrosian","year":"2008","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cmi.2019.03.014_bib67","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-2334-14-102","article-title":"Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis","volume":"14","author":"Chuang","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib68","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/CCM.0000000000000933","article-title":"Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study","volume":"43","author":"Cheng","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2019.03.014_bib69","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/CCM.0000000000001029","article-title":"Combination therapy for extreme drug-resistant Acinetobacter baumannii: ready for prime time?","volume":"43","author":"Spellberg","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2019.03.014_bib70","doi-asserted-by":"crossref","first-page":"908.e1","DOI":"10.1016\/j.cmi.2017.10.033","article-title":"Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii","volume":"24","author":"Liang","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.03.014_bib71","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","article-title":"Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis","volume":"21","author":"Jung","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2019.03.014_bib72","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s10096-014-2070-6","article-title":"Comparison of colistin\u2013carbapenem, colistin\u2013sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections","volume":"33","author":"Batirel","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib73","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1128\/AAC.00494-15","article-title":"Polymyxin B in combination with antimicrobials lacking in\u00a0vitro activity versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections","volume":"59","author":"Rigatto","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib74","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cmi.2015.12.010","article-title":"Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia","volume":"22","author":"Freire","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.03.014_bib75","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.medcli.2011.06.024","article-title":"Multidrug and carbapenem-resistant Acinetobacter baumannii infections: factors associated with mortality","volume":"138","author":"Hern\u00e1ndez-Torres","year":"2012","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.cmi.2019.03.014_bib76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s15010-013-0495-y","article-title":"Comparison of colistin and colistin\/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"42","author":"Kalin","year":"2014","journal-title":"Infection"},{"key":"10.1016\/j.cmi.2019.03.014_bib77","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.ajic.2011.12.014","article-title":"Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and\/or carbapenem-resistant Enterobacteriaceae infections","volume":"40","author":"Ku","year":"2012","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.cmi.2019.03.014_bib78","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3855\/jidc.6195","article-title":"Colistin alone or combined with sulbactam or carbapenem against A.\u00a0baumannii in ventilator-associated pneumonia","volume":"9","author":"Yilmaz","year":"2015","journal-title":"J\u00a0Infect Dev Ctries"},{"key":"10.1016\/j.cmi.2019.03.014_bib79","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.cmi.2017.09.016","article-title":"The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii","volume":"24","author":"Amat","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2019.03.014_bib80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/dkw377","article-title":"Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis","volume":"72","author":"Zusman","year":"2017","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib81","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ijantimicag.2017.12.020","article-title":"Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2019.03.014_bib82","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/jac\/dkx368","article-title":"Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis","volume":"73","author":"Kengkla","year":"2018","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib83","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/cid\/cis588","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K.\u00a0pneumoniae: importance of combination therapy","volume":"55","author":"Tumbarello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib84","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1128\/AAC.02166-13","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","author":"Daikos","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib85","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib86","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1093\/cid\/ciy516","article-title":"Optimizing the design and analysis of clinical trials for antibacterials against multidrug-resistant organisms: a white paper from COMBACTE\u2019s STAT-Net","volume":"67","author":"de Kraker","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib87","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/cid\/civ048","article-title":"Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance","volume":"60","author":"Qureshi","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2019.03.014_bib88","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01268-16","article-title":"High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model","volume":"61","author":"Lenhard","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib89","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/jac\/dky027","article-title":"Treatment of infections caused by multidrug-resistant gram-negative bacteria: report of the British society for antimicrobial chemotherapy\/healthcare infection society\/British infection association joint working party","volume":"73","author":"Hawkey","year":"2018","journal-title":"Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2019.03.014_bib90","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00134-015-4079-4","article-title":"Task force on management and prevention of Acinetobacter baumannii infections in the ICU","volume":"41","author":"Garnacho-Montero","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2019.03.014_bib91","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/cid\/ciy375","article-title":"Acinetobacter pneumonia: improving outcomes with early identification and appropriate therapy","volume":"67","author":"Vazquez Guillamet","year":"2018","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19301168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X19301168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:53:04Z","timestamp":1778799184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X19301168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":91,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1198743X19301168"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2019.03.014","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carbapenem-resistant Acinetobacter baumannii: in pursuit of an effective treatment","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2019.03.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}